J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration

Bayer emphasizes Johnson & Johnson’s experience in the cardiovascular field as key asset of the deal. NDA submission for the factor Xa inhibitor is anticipated in 2007.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet